| 초록 |
We investigated the effect of dose quantity on the therapeutic efficacy of oral GLP1 gene therapy. Using a multimodal gene complex (GLP1/PTCA), we showed glycemic improvement drawn for up to 1 week in three progressives diabetic mouse models. To the best of our knowledge, this is the first report of any dosage form of GLP1 agonist for the most extended period of glucose control using a minimal quantity of genes (＜0.5 mg human equivalent dose). Since Rybelsus® is the only FDA-approved oral GLP1 agonist that needs to be taken with 7 or 14 mg daily, oral GLP1/PTCA may provide the first once or bi-monthly oral treatment option for diabetic patients according to allometric principles. This research was funded by a National Research Foundation of Korea (NRF) grant (grant number NRF-2021R1A2C2095113). It was also supported by Basic Science Research Program through the NRF funded by the Ministry of Education(grant number 2021R1A6A1A03046418). |
